NCT06565078View on ClinicalTrials.gov

A Database Survey to Evaluate the Safety of Immune Globulin Subcutaneous (Human), 20% Solution in Participants with Primary Immunodeficiency

RecruitingOBSERVATIONAL
Enrollment

100

Participants

Timeline

Start Date

February 17, 2025

Primary Completion Date

July 31, 2030

Study Completion Date

July 31, 2030

Conditions
Primary Immunodeficiency Diseases (PID)
Interventions
DRUG

Immune Globulin Subcutaneous (Human), 20% Solution

CUVITRU 20% Solution

Trial Locations (1)

Unknown

RECRUITING

Takeda selected site, Tokyo

Sponsors

Lead Sponsor

Takeda
All Listed Sponsors
lead

Takeda

INDUSTRY

NCT06565078 - A Database Survey to Evaluate the Safety of Immune Globulin Subcutaneous (Human), 20% Solution in Participants with Primary Immunodeficiency | Biotech Hunter | Biotech Hunter